TABLE 2.
KRAS mutation status and survival among patients with pancreatic cancer
| Disease‐free survival | Overall survival | |||||||
|---|---|---|---|---|---|---|---|---|
| No. of cases | No. of events | Univariable HR (95% CI) | Multivariable HR a (95% CI) | No. of cases | No. of events | Univariable HR (95% CI) | Multivariable HR a (95% CI) | |
| KRAS mutation | ||||||||
| Wild type | 23 | 15 | 1.00 (referent) | 1.00 (referent) | 23 | 13 | 1.00 (referent) | 1.00 (referent) |
| Mutant | 1072 | 850 | 1.23 (0.74–2.05) | 1.04 (0.62–1.75) | 1125 | 799 | 1.26 (0.73–2.19) | 1.05 (0.60–1.84) |
| p value | 0.43 | 0.87 | 0.40 | 0.86 | ||||
| KRAS VAF | ||||||||
| 1%–9% | 258 | 189 | 1.00 (referent) | 1.00 (referent) | 269 | 172 | 1.00 (referent) | 1.00 (referent) |
| 10%–19% | 479 | 374 | 1.22 (1.02–1.45) | 1.22 (1.02–1.45) | 498 | 348 | 1.27 (1.05–1.52) | 1.19 (0.99–1.44) |
| ≥20% | 335 | 287 | 1.63 (1.35–1.96) | 1.60 (1.32–1.93) | 358 | 279 | 1.70 (1.40–2.05) | 1.52 (1.25–1.85) |
| p trend b | <0.001 | <0.001 | <0.001 | <0.001 | ||||
Abbreviations: CI, confidence interval; HR, hazard ratio; VAF, variant allele frequency.
a
The multivariable Cox regression model initially included age, sex, year of diagnosis, tumor location, histological type, stroma type, lymphatic invasion, venous invasion, neural invasion, cancer stage, resection margin status, receipt of neoadjuvant chemotherapy, and receipt of adjuvant chemotherapy. Backward elimination with a threshold p of 0.05 was conducted to select variables for the final models. The variables that remained in the final models are described in Table S2.
b
p trend was calculated by entering KRAS VAF (continuous) in the Cox regression model.